Remove 2019 Remove Access Remove Data Remove Safety
article thumbnail

Surgeon General’s Advisory Highlights Need for Further Cannabis Regulation, Not Criminalization

NORML

” Specifically, federal and state data finds that teen cannabis use has declined in past years – during the same time that many states have legalized and regulated the use of cannabis by adults. According to an August 2019 federal report , past-year marijuana use by those ages 12 to 17 has fallen consistently since 2002, from 15.8

Education 229
article thumbnail

Update: Massachusetts Marijuana Establishments Surpass $2 Billion in Gross Sales

Cannabis Law Report

This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.

Marijuana 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New- ANH-Intl Special Report: Is safety the new gremlin for CBD regulation?

Cannabis Law Report

We take a look at where CBD regulation might be going and whether we should be concerned about safety writes Rob Verkerk PhD, scientific and executive director, ANH-Intl. We take a look at where CBD regulation might be going and whether we should be concerned about safety. A new ‘problem’: safety. ? A new ‘problem’: safety.

Safety 59
article thumbnail

Survey Reveals Almost Half of Canada’s MMJ Patients Reduced Their Alcohol and Opioid Consumption

Veriheal

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Accessed August 2021. 2019 Mar; 4(1): 73–84.

article thumbnail

Tyson and Holyfield Announce Edibles, Texas’ Medical Cannabis Gains, and Big Hemp Study

Veriheal

According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Texas’ consistent gains can, in large part, be attributed to its recent efforts to increase access to its program.

Edibles 97